Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
About this item
Full title
Author / Creator
Sabatine, Marc S , Giugliano, Robert P , Wiviott, Stephen D , Raal, Frederick J , Blom, Dirk J , Robinson, Jennifer , Ballantyne, Christie M , Somaratne, Ransi , Legg, Jason , Wasserman, Scott M , Scott, Robert , Koren, Michael J , Stein, Evan A and Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In two randomized trials, evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9), reduced LDL cholesterol levels by 61%. In an exploratory analysis, the incidence of cardiovascular events was reduced in the evolocumab group.
Reduction in low-density lipoprotein (LDL) cholesterol levels has proved to...
Alternative Titles
Full title
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Authors, Artists and Contributors
Author / Creator
Giugliano, Robert P
Wiviott, Stephen D
Raal, Frederick J
Blom, Dirk J
Robinson, Jennifer
Ballantyne, Christie M
Somaratne, Ransi
Legg, Jason
Wasserman, Scott M
Scott, Robert
Koren, Michael J
Stein, Evan A
Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1674203836
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1674203836
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1500858
